Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
59
Recruiting, any sponsor type, condition "posttraumatic stress disorder"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed251
59 trials
Showing 1 to 25, recently updated first.
- BXCL501 After Stress to Increase Recovery SuccessPivotal-lookingRecruiting
University of North Carolina, Chapel HillAcademic, hospital or other
NCT06943404 · 100 participants (planned) · Start Feb 23, 2026 · Primary completion Sep 29, 2027
Drug: BXCL501 (dexmedetomidine HCl); Placebo · For: Acute Stress Reaction; Acute Stress Disorder; Post-traumatic Stress Disorder
Sites: Jacksonville, Florida; Lakeland, Florida; St Louis, Missouri · 4 sites in all
VA Office of Research and DevelopmentFederal agency
NCT05776056 · 70 participants (planned) · Start Feb 5, 2024 · Primary completion Mar 31, 2027
Drug: Methylphenidate; Placebo · For: Posttraumatic Stress Disorder (PTSD)
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Seattle, Washington
- Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPivotal-lookingRecruiting
COMPASS PathwaysIndustry
NCT07570654 · 300 participants (planned) · Start Sep 14, 2026 · Primary completion Nov 2028
Drug: COMP360 psilocybin · For: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms and 1 more
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 20 sites in all
- Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral InjuryPivotal-lookingRecruiting
Herzog HospitalAcademic, hospital or other
NCT06394284 · 60 participants (planned) · Start May 20, 2024 · Primary completion Dec 31, 2027
Drug: MDMA-AT · For: PTSD, Post Traumatic Stress Disorder; Moral Injury
Sites: Jerusalem, Israel
- An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSDPivotal-lookingRecruiting
Transcend TherapeuticsIndustry
NCT07836647 · 300 participants (planned) · Start Sep 25, 2026 · Primary completion Feb 2028
Drug: TSND-201; Placebo · For: Post Traumatic Stress Disorder
Sites: Denver, Colorado; Bradenton, Florida; Orlando, Florida · 9 sites in all
- Psilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT07226232 · 240 participants (planned) · Start Aug 3, 2026 · Primary completion Dec 2, 2030
Drug: Psilocybin; Psilocybin · For: Major Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Portland, Oregon · 5 sites in all
- Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSDRecruiting
Guy SchusheimAcademic, hospital or other
NCT05732155 · 60 participants (planned) · Start Jun 1, 2023 · Primary completion Jun 1, 2027
Drug: methylenedioxymethamphetamine · For: Post Traumatic Stress Disorder; MDMA ('Ecstasy')
Sites: Afula, Israel
- Suvorexant for Treatment of AUD and PTSDRecruiting
Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
NCT06679062 · 76 participants (planned) · Start Jul 16, 2025 · Primary completion Mar 2027
Drug: Suvorexant · For: Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD); Insomnia
Sites: Los Angeles, California; Houston, Texas
Bronx VA Medical CenterFederal agency
NCT06418178 · 60 participants (planned) · Start Jun 3, 2025 · Primary completion Oct 2029
Drug: Midomafetamine · For: Posttraumatic Stress Disorder
Sites: The Bronx, New York
Stanford UniversityAcademic, hospital or other
NCT06577636 · 42 participants (planned) · Start Jul 21, 2025 · Primary completion Dec 2028
Drug: Propofol · For: PTSD; Post-traumatic Stress Disorder
Sites: Stanford, California
Summit Hyperbarics and WellnessAcademic, hospital or other
NCT07852728 · 54 participants (planned) · Start Sep 11, 2026 · Primary completion Sep 11, 2027
Drug: Hyperbaric Oxygen Therapy (HBOT) · For: Traumatic Brain Injury; PTSD - Post Traumatic Stress Disorder; Anxiety and 2 more
Sites: Boise, Idaho
Summit Hyperbarics and WellnessAcademic, hospital or other
NCT07849465 · 34 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2027
Drug: Hyperbaric Oxygen Therapy (HBOT) · For: Traumatic Brain Injury (TBI) Patients; Post Concussive Symptoms; PTSD
Sites: Boise, Idaho
- Safety and Efficacy of HB-1 for Post-Traumatic Stress DisorderPivotal-lookingRecruiting
HB BioTech, LLCIndustry
NCT07499440 · 200 participants (planned) · Start Jun 3, 2026 · Primary completion Sep 2027
Drug: HB-1; Placebo · For: PTSD; Mental Illness
Sites: Deakin, Australia; Charlestown, Australia; Darlinghurst, Australia · 16 sites in all
- Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient StudyRecruiting
Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
NCT06335407 · 10 participants (planned) · Start Jul 28, 2025 · Primary completion Feb 27, 2027
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg; Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg · For: Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD)
Sites: West Haven, Connecticut
- Inflammatory Challenge and FearPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06630884 · 288 participants (planned) · Start Mar 28, 2025 · Primary completion Nov 2028
Drug: Typhoid VI Polysaccharide Vaccine Injectable Solution · For: Posttraumatic Stress Disorder (PTSD)
Sites: San Francisco, California
- Dexmedetomidine Combined With Transcutaneous Vagus Nerve Stimulation (taVNS) Can Reduce the Incidence of PTSD in Trauma Patients After SurgeryPivotal-lookingRecruiting
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
NCT07813962 · 300 participants (planned) · Start Sep 12, 2026 · Primary completion Aug 1, 2027
Drug: Dexmedetomidine 0.1μg/kg/h · For: PTSD - Post Traumatic Stress Disorder; taVNS; Dexmedetomidine
Sites: Nantong, China
- Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in AdultsPivotal-lookingRecruiting
University of NebraskaAcademic, hospital or other
NCT05269459 · 140 participants (planned) · Start Dec 1, 2022 · Primary completion Dec 2028
Drug: Cannabidiol Administered as Nantheia ATL5; Placebo · For: PTSD
Sites: Omaha, Nebraska
- An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)Pivotal-lookingRecruiting
Transcend TherapeuticsIndustry
NCT07456696 · 300 participants (planned) · Start Apr 2, 2026 · Primary completion Dec 2027
Drug: TSND-201; Placebo · For: Post Traumatic Stress Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 37 sites in all
Dr. Yuliya KnyahnytskaAcademic, hospital or other
NCT07009158 · 30 participants (planned) · Start Mar 31, 2026 · Primary completion Sep 2029
Drug: Ketamine Infusion · For: Chronic Pain; Posttraumatic Stress Disorder (PTSD)
Sites: Kingston, Canada
- Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)Recruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06989957 · 40 participants (planned) · Start Sep 17, 2025 · Primary completion Aug 2028
Drug: Psilocybin; Psilocybin and 2 more · For: Posttraumatic Stress Disorder
Sites: Baltimore, Maryland
Yale UniversityAcademic, hospital or other
NCT06371404 · 150 participants (planned) · Start Jun 5, 2024 · Primary completion Jun 1, 2030
Drug: Bavarostat · For: Alcohol Use Disorder; Post Traumatic Stress Disorder
Sites: New Haven, Connecticut
Stephen Robert MarderFederal agency
NCT05790239 · 40 participants (planned) · Start Mar 1, 2025 · Primary completion Mar 2028
Drug: 3,4-methylenedioxymethamphetamine; d-amphetamine · For: Post Traumatic Stress Disorder
Sites: Los Angeles, California · 2 sites in all
- MDMA-Assisted CBCT for PTSD vs CBCT RCTRecruiting
RemedyIndustry
NCT06044675 · 60 participants (planned) · Start Nov 15, 2024 · Primary completion Mar 31, 2027
Drug: MDMA assisted psychotherapy · For: Post Traumatic Stress Disorder
Sites: Toronto, Canada
- The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSDPivotal-lookingRecruiting
University of HaifaAcademic, hospital or other
NCT07771530 · 160 participants (planned) · Start Aug 1, 2026 · Primary completion Aug 1, 2028
Drug: methylphenidate (Ritalin®); Reboxetine and 2 more · For: PTSD; Posttraumatic Stress Disorder
Sites: Haifa, Israel
University of HaifaAcademic, hospital or other
NCT05133804 · 53 participants (planned) · Start Jun 1, 2022 · Primary completion Oct 1, 2026
Drug: Methylphenidate; Reboxetine and 2 more · For: Posttraumatic Stress Disorder
Sites: Afula, Israel; Haifa, Israel; Netanya, Israel
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.